Articles

1. Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM

   • Euibeom Shin
   • Yifan Yu
   • Murali Ramanathan

   Original Paper 24 April 2024

   

2. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site

   • Leonid Gibiansky
   • Chee M. Ng
   • Ekaterina Gibiansky

   Original Paper 19 April 2024

   

3. A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction

   • Xueyong Li
   • Yu Cheng
   • Hongqiang Qiu

   Original Paper 16 April 2024

   

4. Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles

   • Deok Yong Yoon
   • Michael J. Daniels
   • the DMD MR Biomarker Steering Committee

   Original Paper 12 April 2024

   

5. Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches

   • Morgane Philipp
   • Simon Buatois
   • France Mentré

   Original Paper 09 April 2024

   

6. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

   • Azmi Nasser
   • Roberto Gomeni
   • Jonathan Rubin

   Original Paper Open access 05 April 2024

   

7. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions

   • Tongtong Li
   • Sufeng Zhou
   • Feng Shao

   Original Paper 30 March 2024

   

8. Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab

   • Monica Simeoni
   • Shuying Yang
   • Richard Dimelow

   Original Paper Open access 29 March 2024

   

9. On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models

   • Alexander Janssen
   • Frank C. Bennis
   • for the OPTI-CLOT Study Group and SYMPHONY Consortium

   Original Paper Open access 26 March 2024

   

10. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing

    • Jasmine H. Hughes
    • Janel Long-Boyle
    • Ron J. Keizer

    Original Paper Open access 23 March 2024

    

11. Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel

    • David Wang
    • Chris Jackson
    • Stephen Duffull

    Original Paper Open access 19 March 2024

    

12. Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling

    • Miriam Schirru
    • Hamza Charef
    • Fahima Nekka

    Original Paper 17 March 2024

    

13. An industry perspective on current QSP trends in drug development

    • Lourdes Cucurull-Sanchez

    Original Paper Open access 05 March 2024

    

14. Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis

    • Nikolaos Tsamandouras
    • Ruolun Qiu
    • Timothy Nicholas

    Original Paper Open access 03 March 2024

    

15. Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics

    • Sihem Ait-Oudhia

    Editorial 28 February 2024 Pages: 95 - 100

    

16. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics

    • Krutika Patidar
    • Nikhil Pillai
    • Panteleimon D. Mavroudis

    Original Paper Open access 24 February 2024

    

17. Subgroup identification-based model selection to improve the predictive performance of individualized dosing

    • Hiie Soeorg
    • Riste Kalamees
    • Tuuli Metsvaht

    Original Paper 24 February 2024

    

18. Thoughts on plagiarism and the case against Claudine Gay

    • Peter L. Bonate

    Editorial 15 February 2024 Pages: 1 - 4

    

19. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension

    • Janneke M. Brussee
    • Patricia N. Sidharta
    • Andreas Krause

    Original Paper 08 February 2024

    

20. A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations

    • Franziska Schaedeli Stark
    • Clarisse Chavanne
    • Hanna E. Silber Baumann

    Original Paper Open access 03 February 2024

    

21. Correction: External control arms for rare diseases: building a body of supporting evidence

    • Artak Khachatryan
    • Stephanie H Read
    • Terri Madison

    Correction Open access 19 January 2024 Pages: 93 - 93

22. How drug onset rate and duration of action affect drug forgiveness

    • Elias D. Clark
    • Sean D. Lawley

    Original Paper 10 January 2024

    

23. Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations

    • Sebastian T. Tandar
    • Linda B.S. Aulin
    • J. G. Coen van Hasselt

    Original Paper 26 November 2023

    

24. Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms

    • Pieter-Jan De Sutter
    • Elke Gasthuys
    • An Vermeulen

    Original Paper 12 November 2023

    

25. Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model

    • Euibeom Shin
    • Murali Ramanathan

    Original Paper 11 November 2023 Pages: 101 - 108

    

26. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs

    • Hsien-Wei Huang
    • Shengjia Wu
    • Dhaval K. Shah

    Original Paper 10 November 2023

    

27. Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

    • Ari Brekkan
    • Rocío Lledo-Garcia
    • Elodie L. Plan

    Original Paper Open access 09 November 2023 Pages: 65 - 75

    

28. Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model

    • Heinrich J. Huber
    • Hitesh B. Mistry

    Original Paper Open access 06 November 2023 Pages: 169 - 185

    

29. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations

    • Amitava Mitra
    • Jong Bong Lee
    • Rajesh Krishna

    Review Paper 04 November 2023 Pages: 475 - 493

    

30. Learning pharmacometric covariate model structures with symbolic regression networks

    • Ylva Wahlquist
    • Jesper Sundell
    • Kristian Soltesz

    Original Paper Open access 21 October 2023 Pages: 155 - 167

    

31. Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)

    • Yanke Yu
    • Michael E. Rothenberg
    • Annemarie N. Lekkerkerker

    Original Paper 20 October 2023 Pages: 141 - 153

    

32. Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy

    • Mary P Choules
    • Peter L. Bonate
    • Jared Weddell

    Original Paper Open access 17 October 2023

    

33. Low-dimensional neural ODEs and their application in pharmacokinetics

    • Dominic Stefan Bräm
    • Uri Nahum
    • Gilbert Koch

    Original Paper Open access 14 October 2023 Pages: 123 - 140

    

34. Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)

    • Bruna Scheuher
    • Khem Raj Ghusinga
    • Alison Betts

    Original Paper Open access 03 October 2023

    

35. Correction to: Training the next generation of pharmacometric modelers: a multisector perspective

    • Peter L. Bonate
    • Jeffrey S. Barrett
    • Hao Zhu

    Correction 05 September 2023 Pages: 89 - 89

36. Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin

    • Mary P. Choules
    • Peiying Zuo
    • Peter Bonate

    ORIGINAL PAPER Open access 26 August 2023

    

37. Training the next generation of pharmacometric modelers: a multisector perspective

    • Peter L. Bonate
    • Jeffrey S. Barrett
    • Hao Zhu

    Commentary 13 August 2023 Pages: 5 - 31

    

38. Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study

    • Juanjuan Jiang
    • Li Xu
    • Lei Tian

    Original Paper 11 August 2023 Pages: 77 - 87

    

39. Optimal sample selection applied to information rich, dense data

    • David Wang
    • Tak Hung
    • Stephen Duffull

    Commentary 10 August 2023 Pages: 33 - 37

    

40. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies

    • Sanika Naware
    • David Bussing
    • Dhaval K. Shah

    Original Paper 09 August 2023

    

41. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease

    • Gilles Tiraboschi
    • David Marchionni
    • Fabrice Hurbin

    Original Paper Open access 03 August 2023 Pages: 461 - 474

    

42. Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases

    • Hugo Geerts
    • Silke Bergeler
    • Piet H. van der Graaf

    Review Paper 28 July 2023

    

43. Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory

    • Carla White
    • Vivi Rottschäfer
    • Lloyd Bridge

    Correction Open access 26 July 2023 Pages: 91 - 91

44. Go beyond the limits of genetic algorithm in daily covariate selection practice

    • D. Ronchi
    • E. M. Tosca
    • P. Magni

    Original Paper Open access 26 July 2023 Pages: 109 - 121

    

45. Generation and application of avatars in pharmacometric modelling

    • Estelle Chasseloup
    • Andrew C. Hooker
    • Mats O. Karlsson

    Original Paper Open access 24 July 2023 Pages: 411 - 423

    

46. International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs

    • Patrick O. Hanafin
    • Ananya Murthy
    • Gauri G. Rao

    Editorial 22 July 2023 Pages: 243 - 250

    

47. A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory

    • Alessandro De Carlo
    • Elena Maria Tosca
    • Paolo Magni

    OriginalPaper Open access 09 July 2023 Pages: 395 - 409

    

48. Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory

    • Carla White
    • Vivi Rottschäfer
    • Lloyd Bridge

    Original Paper Open access 30 June 2023 Pages: 39 - 63

    

49. Clinical validation of translational antibody PBPK model using tissue distribution data generated with ⁸⁹Zr-immuno-PET imaging

    • Shufang Liu
    • Zhe Li
    • Dhaval K. Shah

    Original Paper 29 June 2023 Pages: 377 - 394

    

50. Assessing the performance of QSP models: biology as the driver for validation

    • Fulya Akpinar Singh
    • Nasrin Afzal
    • Craig J. Thalhauser

    Review Paper Open access 29 June 2023